J Pediatr Neurol 2019; 17(01): 031-037
DOI: 10.1055/s-0037-1608795
Case Report
Georg Thieme Verlag KG Stuttgart · New York

Clinical Course and Treatment in MOG Antibody Seropositive Children: A Case Series

Grace Y. Kim
1  Partners Pediatric Multiple Sclerosis Center, Massachusetts General Hospital, Boston, Massachusetts, United States
,
Shrishti Saxena
2  Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, Massachusetts, United States
,
Tanuja Chitnis
1  Partners Pediatric Multiple Sclerosis Center, Massachusetts General Hospital, Boston, Massachusetts, United States
2  Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, Massachusetts, United States
› Author Affiliations
Further Information

Publication History

18 July 2017

16 October 2017

Publication Date:
22 November 2017 (eFirst)

Abstract

Myelin oligodendrocyte glycoprotein (MOG) antibodies have been associated with pediatric demyelinating diseases. The clinical course in a patient with MOG positivity is variable but not well-characterized. Here, we describe the clinical course and treatment in MOG antibody positive demyelinating diseases in our pediatric population. This case series is of 13 patients who tested MOG antibody positive: two relapsing remitting multiple sclerosis (RR-MS), seven acute demyelinating encephalomyelitis (ADEM) or ADEM-optic neuritis (ADEM-ON), two clinically isolated syndrome (CIS), and two neuromyelitis optica (NMO). These patients appear to have more relapses, requiring more medications including IV steroids and IVIG. These patients are also more likely to start on disease modifying therapy (DMT) earlier, and β-interferon appears to not prevent relapses. MOG antibody positivity could provide as a marker for predicting frequent relapses in RR-MS and NMO patients, allowing for therapeutic intervention with earlier DMT.

Funding

This work is supported by the Guthy Jackson Charitable Foundation (T.C.).